15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $7M | -$136M | 0.0% | -2222.4% | -65.8% | -42.7% | -$112M | — | $47M |
| 2024 | $14M | -$186M | 0.0% | -1542.6% | -58.4% | -42.3% | -$124M | — | $36M |
| 2023 | $64M | -$161M | 0.0% | -299.9% | -43.7% | -31.8% | -$138M | — | $42M |
| 2022 | $96M | -$282M | 0.0% | -320.2% | -58.2% | -39.9% | -$284M | — | $61M |
| 2021 | $56M | -$212M | 0.0% | -388.6% | -31.3% | -23.0% | -$214M | — | $134M |
| 2020 | $31M | -$173M | 0.0% | -407.5% | -45.1% | -27.9% | -$44M | — | $167M |
| 2019 | $11M | -$98M | 0.0% | -943.1% | -40.1% | -32.5% | -$91M | — | $100M |
| 2018 | $5M | -$67M | 0.0% | -1415.4% | -41.5% | -31.3% | -$41M | $18M | $191M |
| 2017 | $4M | -$43M | 0.0% | -1025.9% | -55.6% | -40.8% | -$39M | $19M | $89M |
| 2016 | $4M | -$33M | 0.0% | -726.1% | -45.7% | -35.2% | -$30M | $13M | $89M |
| 2015 | — | -$30M | — | — | -78.8% | -44.1% | — | $22M | $65M |
| 2014 | — | -$26M | — | — | -91.3% | -50.6% | — | $20M | $49M |
| 2014 | — | -$93M | — | — | -206.9% | -188.3% | — | — | $48M |
| 2013 | — | -$21M | — | — | -41.1% | -37.6% | — | $2M | $54M |
| 2013 | — | -$81M | — | — | 121.6% | -350.6% | — | $2M | $19M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $2M | -$30M | 0.0% | -1495.4% | -19.7% | -11.6% | -$23M | — | $32M |
| Mar '26 | $1M | -$31M | 0.0% | -2540.4% | -17.4% | -11.0% | -$31M | — | $40M |
| Dec '25 | $1M | -$32M | 0.0% | -2536.2% | -15.6% | -10.2% | -$25M | — | $47M |
| Sep '25 | $2M | -$32M | 0.0% | -1995.1% | -13.8% | -9.4% | -$27M | — | $41M |
| Jun '25 | $2M | -$34M | 0.0% | -1938.5% | -13.0% | -9.2% | -$26M | — | $41M |
| Mar '25 | $2M | -$38M | 0.0% | -2534.1% | -13.0% | -9.4% | -$35M | — | $45M |
| Dec '24 | $2M | -$52M | 0.0% | -3319.8% | -16.4% | -11.8% | -$28M | — | $36M |
| Sep '24 | $3M | -$48M | 0.0% | -1703.9% | -13.2% | -9.6% | -$30M | — | $38M |
| Jun '24 | $7M | -$38M | 0.0% | -665.7% | -9.7% | -7.3% | -$32M | — | $37M |
| Mar '24 | $2M | -$48M | 0.0% | -2652.9% | -11.3% | -8.4% | -$33M | — | $121M |
| Dec '23 | $2M | -$44M | 0.0% | -2868.4% | -12.0% | -8.7% | -$37M | — | $42M |
| Sep '23 | $2M | -$45M | 0.0% | -2637.8% | -11.2% | -8.3% | -$39M | — | $33M |
| Jun '23 | $933000 | -$53M | 0.0% | -6705.8% | -12.1% | -9.0% | -$31M | — | $47M |
| Mar '23 | $59M | -$19M | 0.0% | -48.5% | -4.0% | -3.0% | -$32M | — | $42M |
| Dec '22 | $44M | -$56M | 0.0% | -145.2% | -11.6% | -8.0% | -$82M | — | $61M |
| Sep '22 | $15M | -$84M | 0.0% | -576.7% | -16.1% | -11.2% | -$64M | — | $82M |
| Jun '22 | $19M | -$76M | 0.0% | -448.1% | -13.1% | -9.4% | -$63M | — | $55M |
| Mar '22 | $18M | -$66M | 0.0% | -404.4% | -10.4% | -7.7% | -$75M | — | $65M |
| Dec '21 | $17M | -$69M | 0.0% | -406.5% | -10.1% | -7.4% | -$89M | — | $134M |
| Sep '21 | $14M | -$43M | 0.0% | -384.0% | -5.9% | -4.4% | -$48M | — | $129M |
How the market has priced FATE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, FATE THERAPEUTICS INC's revenue has declined 26.7% per year. These are computed facts, not advice.
As of FY2025, FATE THERAPEUTICS INC reported — of total debt against $47M of cash.
In FY2025, gross margin was —, operating margin -2222.4%, and net margin -2051.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.